SR9009 / SR9011
Metabolic Health · REV-ERB agonist / exercise mimetic
Tier D
What this is
WADA coverage: Rev-erbalpha agonists, SR9009 and SR9011. Added because these compounds are common in performance-enhancement marketplaces despite lacking approved human use.
Mechanism
REV-ERB agonists are marketed as endurance and fat-loss research chemicals based on circadian/metabolic signaling, but most claims are preclinical or gray-market extrapolation.
Dose & route
No approved human dose
Citations
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.